C W Lees
Overview
Explore the profile of C W Lees including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kennedy N, Rhatigan E, Arnott I, Noble C, Shand A, Satsangi J, et al.
Aliment Pharmacol Ther
. 2013 Oct;
38(10):1255-66.
PMID: 24117596
Background: Thiopurines maintain remission and modify disease course in inflammatory bowel disease. Use is limited by intolerance and subsequent drug withdrawal in approximately 17% of patients treated with azathioprine. Previous...
12.
Reinisch W, Chowers Y, Danese S, Dignass A, Gomollon F, Haagen Nielsen O, et al.
Aliment Pharmacol Ther
. 2013 Oct;
38(9):1109-18.
PMID: 24099472
Background: Iron deficiency is a common and undertreated problem in inflammatory bowel disease (IBD). Aim: To develop an online tool to support treatment choice at the patient-specific level. Methods: Using...
13.
Hare N, Hunt D, Venugopal K, Ho G, Beez T, Lees C, et al.
QJM
. 2012 Jan;
107(1):51-5.
PMID: 22240391
No abstract available.
14.
Lees C, Barrett J, Parkes M, Satsangi J
Gut
. 2011 Feb;
60(12):1739-53.
PMID: 21300624
Complex disease genetics has been revolutionised in recent years by the advent of genome-wide association (GWA) studies. The chronic inflammatory bowel diseases (IBDs), Crohn's disease and ulcerative colitis have seen...
15.
Parisinos C, Lees C, Wallace W, Satsangi J
Thorax
. 2011 Jan;
66(12):1109-10.
PMID: 21233484
Natalizumab is a humanised monoclonal antibody targeting the lymphocyte adhesion molecule a4 integrin, with proven efficacy in multiple sclerosis (MS) and Crohn's disease (CD). The development of sarcoidosis with extrapulmonary...
16.
Parisinos C, McIntyre V, Heron T, Subedi D, Arnott I, Mowat C, et al.
Inflamm Bowel Dis
. 2009 Nov;
16(7):1219-26.
PMID: 19924804
Background: Magnetic resonance follow-through (MRFT) is a new cross-sectional imaging modality with the potential to accurately stage ileal Crohn's disease (CD), while avoiding ionizing radiation and the discomfort associated with...
17.
Lees C, Critchley J, Chee N, Beez T, Gailer R, Williams A, et al.
Inflamm Bowel Dis
. 2009 Jul;
15(11):1621-9.
PMID: 19618462
Background: It has been variously reported that women with inflammatory bowel disease (IBD) have an increased risk of cervical dysplasia. We aimed to assess in a large, accurately phenotyped, case-controlled...
18.
Ho G, Mowat A, Potts L, Cahill A, Mowat C, Lees C, et al.
Aliment Pharmacol Ther
. 2009 Feb;
29(5):527-34.
PMID: 19183339
Background: Adalimumab is a second generation humanized anti-tumour necrosis factor (TNF) monoclonal antibody with established efficacy in Crohn's disease (CD). Aims: To evaluate the efficacy and safety of adalimumab on...
19.
Lees C, Ali A, Thompson A, Ho G, Forsythe R, Marquez L, et al.
Aliment Pharmacol Ther
. 2009 Jan;
29(3):286-97.
PMID: 19132970
Background: Anti-TNF agents are now widely used in Crohn's disease (CD), and in ulcerative colitis (UC). Aim: To review the safety profile of anti-TNF agents in all patients treated with...
20.
Noble C, Abbas A, Cornelius J, Lees C, Ho G, Toy K, et al.
Gut
. 2008 Jun;
57(10):1398-405.
PMID: 18523026
Objective: To investigate differential intestinal gene expression in patients with ulcerative colitis and in controls. Design: Genome-wide expression study (41,058 expression sequence tags, 215 biopsies). Setting: Western General Hospital, Edinburgh,...